Trials / Unknown
UnknownNCT02488382
Lonquek for Autologous Stem Cell Mobilization
Lonquek (Lipegfilgrastim) for Stem Cell Mobilization of Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma and Lymphoma
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Sheba Medical Center · Other Government
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the efficacy and tolerability of Lonquek which is a pegylated (long-acting) version of Filgrastim recombinant human G-CSF (G-CSF) in mobilizing sufficient number of stem cells for autologous stem cell transplantation in patients with lymphoma and multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lonquek | Patients will be given a single fixed dose of Lonquek (Teva LTD), 12-mg subcutaneously. |
Timeline
- Start date
- 2017-07-01
- Primary completion
- 2018-07-01
- Completion
- 2020-07-01
- First posted
- 2015-07-02
- Last updated
- 2017-10-17
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT02488382. Inclusion in this directory is not an endorsement.